Rani Therapeutics Holdings, Inc. (RANI) P/S ratio

P/S ratio today
22.7×

Rani Therapeutics Holdings, Inc. (RANI) trades at 22.7× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 54.7×. That is 44.1% higher than the 37.9× of fiscal 2024. Figures as of 18 Nov 2026, 06:30 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
22.7×
P/S ratio, fiscal 2025
54.7×
Change on fiscal 2024
+44.1%
Highest on record
116.6×fiscal 2021
Lowest on record
37.9×fiscal 2024
Fiscal years on record
32021–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Rani Therapeutics Holdings, Inc. P/S ratio, in more detail

Today's figure is 58.6% below the fiscal 2025 year-end.

Across the 3 fiscal year-ends on record (2021–2025), the highest was 116.6× in fiscal 2021 and the lowest 37.9× in fiscal 2024. Today's P/S ratio is at or below every one of the 3 fiscal year-ends on record; their median is 54.7×.

History · 3 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Rani Therapeutics Holdings, Inc. P/S ratio, year by year

Rani Therapeutics Holdings, Inc. (RANI) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today22.7×—$0.56—
202554.7× 44.1% up$1.35$0.02
202437.9×—$1.37$0.04
2023——$3.32—
2022——$5.90—
2021116.6×—$16.35$0.14

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on RANI

Rani Therapeutics Holdings, Inc., figure by figure

Rani Therapeutics Holdings, Inc. (RANI) overview: price, valuation and scorecard

Rani Therapeutics Holdings, Inc. P/S ratio: questions and answers

What is Rani Therapeutics Holdings, Inc.'s P/S ratio?

Rani Therapeutics Holdings, Inc. (RANI) trades at 22.7× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 54.7×. That is 44.1% higher than the 37.9× of fiscal 2024.

Is Rani Therapeutics Holdings, Inc.'s P/S ratio high or low compared with its own history?

Today's P/S ratio is at or below every one of the 3 fiscal year-ends on record; their median is 54.7×.

What are the highest and lowest P/S ratio figures on record for Rani Therapeutics Holdings, Inc.?

Across the 3 fiscal year-ends on record (2021–2025), the highest was 116.6× in fiscal 2021 and the lowest 37.9× in fiscal 2024.

How is Rani Therapeutics Holdings, Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Rani Therapeutics Holdings, Inc. (RANI) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/RANI/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.